RNAC
Cartesian Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
RNAC fundamentals
Cartesian Therapeutics (RNAC) released its earnings on Aug 7, 2025: revenue was 298.00K (YoY -99.11%), missed estimates; EPS was 0.5 (YoY -13.79%), beat estimates.
Revenue / YoY
298.00K
-99.11%
EPS / YoY
0.5
-13.79%
Report date
Aug 7, 2025
EPS
Revenue
Revenue & Expenses
RNAC has released its 2025 Q3 earnings report, with revenue of 452.00K, reflecting a YoY change of 16.80%, and net profit of -35.90M, showing a YoY change of -48.46%. The Sankey diagram below clearly presents RNAC's revenue sources and cost distribution.
Key Indicators
Cartesian Therapeutics (RNAC) key financial stats and ratios, covering profitability, financial health, and leverage.
Cartesian Therapeutics (RNAC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Cartesian Therapeutics (RNAC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cartesian Therapeutics (RNAC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Cartesian Therapeutics (RNAC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Cartesian Therapeutics (RNAC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is the revenue and EPS growth rate for Cartesian Therapeutics year over year?What is Cartesian Therapeutics's latest dividend and current dividend yield?What is the market's earnings forecast for Cartesian Therapeutics next quarter?What is Cartesian Therapeutics's gross profit margin?What does Cartesian Therapeutics do and what are its main business segments?What guidance did Cartesian Therapeutics's management provide for the next earnings period?What were the key takeaways from Cartesian Therapeutics’s earnings call?What factors drove the changes in Cartesian Therapeutics's revenue and profit?
